Osaka Medical and Pharmaceutical University · Faculty of Medicine / Graduate School of Medicine · 講師

Research keywordsprostate cancer・metastatic renal cell carcinoma・urothelial carcinoma・immune checkpoint therapy・triplet therapy・PARP inhibitor sensitivity・urologic oncology outcomes

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Clinical Outcomes and Clinicopathological Features of Primary Urethral Carcinoma: A Multicenter Retrospective Study in Japan.2026 · International journal of urology : official journal of the Japanese Urological Association / 33 / 2
• Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma.2026 · Scientific reports / 16 / 1
• The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI Therapy.2026 · The Prostate
• Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis.2026 · BJU international / 137 / 2

• 膀胱がん治療QOL向上を目指す包括的網羅解析による治療戦略開発2025
• 包括的網羅解析によるPARP阻害剤薬剤耐性メカニズムの解明2023
• 前立腺がんにおけるCRISPR/Cas9スクリーニングによる新規ターゲット遺伝子の同定2022
• 進行膀胱癌（転移を含む）に対するPDL1抗体併用硼素中性子補足療法の治療効果2021

• Official profile
• ORCID